These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 35649657

  • 1. Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer.
    Lopez de Rodas M, Nagineni V, Ravi A, Datar IJ, Mino-Kenudson M, Corredor G, Barrera C, Behlman L, Rimm DL, Herbst RS, Madabhushi A, Riess JW, Velcheti V, Hellmann MD, Gainor J, Schalper KA.
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35649657
    [Abstract] [Full Text] [Related]

  • 2. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM, Helal DS, Sabry NM, Abo El-Nasr M.
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP, Liao RQ, Tu HY, Wang WJ, Dong ZY, Huang SM, Guo WB, Gou LY, Sun HW, Zhang Q, Xie Z, Yan LX, Su J, Yang JJ, Zhong WZ, Zhang XC, Wu YL.
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. TCF1+PD-1+ tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer.
    Koh J, Kim S, Woo YD, Song SG, Yim J, Han B, Lim S, Ahn HK, Mun S, Kim JS, Keam B, Kim YA, Lee SH, Jeon YK, Chung DH.
    Eur J Cancer; 2022 Oct; 174():10-20. PubMed ID: 35970031
    [Abstract] [Full Text] [Related]

  • 7. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R, Liu C, Zheng S, Wang X, Feng X, Li H, Sun N, He J.
    Cancer Biol Med; 2020 Aug 15; 17(3):768-781. PubMed ID: 32944405
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
    Toki MI, Mani N, Smithy JW, Liu Y, Altan M, Wasserman B, Tuktamyshov R, Schalper K, Syrigos KN, Rimm DL.
    J Thorac Oncol; 2018 Dec 15; 13(12):1884-1896. PubMed ID: 30267840
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y, Lin D, Gao Q, Zhou H, Liao W, Yao H.
    JAMA Netw Open; 2019 Jul 03; 2(7):e196879. PubMed ID: 31290993
    [Abstract] [Full Text] [Related]

  • 12. Immune Checkpoint Markers in Superficial Angiosarcomas: PD-L1, PD-1, CD8, LAG-3, and Tumor-Infiltrating Lymphocytes.
    Googe PB, Flores K, Jenkins F, Merritt B, Moschos SJ, Grilley-Olson JE.
    Am J Dermatopathol; 2021 Aug 01; 43(8):556-559. PubMed ID: 33156018
    [Abstract] [Full Text] [Related]

  • 13. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
    Kim CG, Kim G, Kim KH, Park S, Shin S, Yeo D, Shim HS, Yoon HI, Park SY, Ha SJ, Kim HR.
    J Immunother Cancer; 2021 Dec 01; 9(12):. PubMed ID: 34907028
    [Abstract] [Full Text] [Related]

  • 14. Programmed death ligand 1 expression and CD8+ tumor-infiltrating lymphocyte density differences between paired primary and brain metastatic lesions in non-small cell lung cancer.
    Zhou J, Gong Z, Jia Q, Wu Y, Yang ZZ, Zhu B.
    Biochem Biophys Res Commun; 2018 Apr 15; 498(4):751-757. PubMed ID: 29526752
    [Abstract] [Full Text] [Related]

  • 15. Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis.
    Ma J, Li J, He N, Qian M, Lu Y, Wang X, Wu K.
    J Transl Med; 2023 Feb 03; 21(1):73. PubMed ID: 36737759
    [Abstract] [Full Text] [Related]

  • 16. T lymphocyte subsets and PD-1 expression on lymphocytes in peripheral blood of patients with non-small cell lung cancer.
    Chen T, Chen H, Lu W, Yao Y.
    Medicine (Baltimore); 2022 Oct 21; 101(42):e31307. PubMed ID: 36281084
    [Abstract] [Full Text] [Related]

  • 17. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K, Cheng G, Zhang F, Zhu G, Xu Y, Yu X, Huang Z, Fan Y.
    Lung Cancer; 2020 Apr 21; 142():98-105. PubMed ID: 32120230
    [Abstract] [Full Text] [Related]

  • 18. Heterogeneity of programmed death-ligand 1 expression and infiltrating lymphocytes in paired resected primary and metastatic non-small cell lung cancer.
    Wu J, Sun W, Yang X, Wang H, Liu X, Chi K, Zhou L, Huang X, Mao L, Zhao S, Ding T, Meng B, Lin D.
    Mod Pathol; 2022 Feb 21; 35(2):218-227. PubMed ID: 34493824
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer.
    Zhang L, Chen Y, Wang H, Xu Z, Wang Y, Li S, Liu J, Chen Y, Luo H, Wu L, Yang Y, Zhang H, Peng H.
    J Immunother Cancer; 2021 Jun 21; 9(6):. PubMed ID: 34140315
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.